Section Arrow
Quote
CORT.NASDAQ
- Corcept Therapeutics
Quotes are at least 15-min delayed:2026/11/04 19:21 EST
After Hours
Last
 79.08
-0.14 (-0.18%)
Bid
74.99
Ask
84
High 82 
Low 79.08 
Volume 76.20K 
Regular Hours (Closed)
Last
 79.22
-2.71 (-3.31%)
Day High 
84.98 
Prev. Close
81.93 
1-M High
122.81 
Volume 
2.20M 
Bid
74.99
Ask
84
Day Low
71.29 
Open
83.25 
1-M Low
79.395 
Market Cap 
8.86B 
Currency 美元 
P/E 182.07 
%Yield -- 
10-SMA 90.01 
20-SMA 103.34 
50-SMA 110.31 
52-W High 126.3833 
52-W Low 28.6601 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.45/5.64
Enterprise Value
8.86B
Balance Sheet
Book Value Per Share
6.53
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
761.41M
Operating Revenue Per Share
4.16
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.11+0.3961+55.48%0.2PE
After Hours 0.941 -0.169 -15.23%
KPTIKaryopharm Therapeutics Inc.0.0729-0.0154-17.44%-- 
After Hours 0.0853 +0.0124 +17.01%
GERNGeron Corp1.08+0.15+16.13%-- 
After Hours 1.07 -0.01 -0.93%
INOInovio Pharmaceuticals1.62-0.04-2.41%-- 
After Hours 1.59 -0.03 -1.85%
RXRXRecursion Pharmaceuticals3.88+0.2+5.43%-- 
After Hours 3.8491 -0.0309 -0.80%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.